New phase II umbrella trial studies novel agents for the management of relapsed ovarian cancer Feb. 9, 2018
Daiichi Sankyo studies DS-1205c with osimertinib for metastatic or unresectable EGFR-mutant NSCLC Feb. 9, 2018
RSS